dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Döhner, Hartmut |
dc.contributor.author | Symeonidis, Argiris |
dc.contributor.author | Deeren, Dries |
dc.contributor.author | Demeter, Judit |
dc.contributor.author | Sanz, Miguel A. |
dc.contributor.author | Anagnostopoulos, Achilles |
dc.contributor.author | Salamero García, Olga |
dc.date.accessioned | 2022-04-08T12:25:08Z |
dc.date.available | 2022-04-08T12:25:08Z |
dc.date.issued | 2021-08 |
dc.identifier.citation | Döhner H, Symeonidis A, Deeren D, Demeter J, Sanz MA, Anagnostopoulos A, et al. Adjunctive Volasertib in Patients with Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. HemaSphere. 2021;5(8):e617. |
dc.identifier.issn | 2572-9241 |
dc.identifier.uri | https://hdl.handle.net/11351/7338 |
dc.description | Teràpia d'inducció estàndard; Volasertib adjuvant; Leucèmia mieloide aguda |
dc.description.sponsorship | This study was funded by Boehringer Ingelheim. |
dc.language.iso | eng |
dc.publisher | Wolters Kluwer Health |
dc.relation.ispartofseries | HemaSphere;5(8) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Leucèmia mieloide aguda - Quimioteràpia - Complicacions |
dc.subject | Persones grans |
dc.subject.mesh | Leukemia, Myeloid, Acute |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | /adverse effects |
dc.title | Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1097/HS9.0000000000000617 |
dc.subject.decs | leucemia mieloide aguda |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://doi.org/10.1097/HS9.0000000000000617 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Döhner H] Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany. [Symeonidis A] Hematology Division, University Hospital, University of Patras Medical School, Patras, Greece. [Deeren D] AZ Delta, Roeselare, Belgium. [Demeter J] Semmelweis University, Budapest, Hungary. [Sanz MA] Department of Hematology, University Hospital La Fe, Valencia, Spain. [Anagnostopoulos A] Hematology Department, General Hospital G. Papanikolaou, Thessaloniki, Greece. [Salamero O] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 34350385 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |